{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of September 2023): No"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2404582"],"location":["United Kingdom"],"study_start_month":["1"],"keyword":["FMPV-1","Cancer-specific vaccine","GM-CSF adjuvant","Neoantigen"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Immune Response to FMPV-1","description":"This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.","dates":{"creation":"2022-01-15"},"accession":"2404582","cross_references":{"ClinicalTrials___gov":["NCT05238558"]}}